Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry

Autor:	Melinda Kaltenbaugh, Liz Garrett-Mayer, Daniel J Mesenhowski, Ronald C. Chen, Charu Aggarwal, Kathryn Finch Mileham, Christiana Davis, Abdul Rahman Jazieh, Alicia L. Patrick, Alexander I. Spira, Jen Hanley Williams, David M. Waterhouse, Richard L. Schilsky, Susan G. Moore, Suanna S. Bruinooge, Eric J. Clayton
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Cancer macromolecular substances medicine.disease Cancer treatment Internal medicine medicine business
Zdroj:	Journal of Clinical Oncology. 39:6509-6509
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2021.39.15_suppl.6509
Popis:	6509 Background: The ASCO Registry was created to analyze the impact of COVID-19 (COVID) on treatment (Tx) and outcomes of patients (pts) with cancer. Methods: The Registry includes pts with 1) a confirmed COVID diagnosis (Dx) and 2) clinically evident cancer receiving Tx/supportive care or resected cancer on adjuvant Tx
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9145b1e6ce07314be9857d5dd043d0ed https://doi.org/10.1200/jco.2021.39.15_suppl.6509 Zobrazit plný text záznamu